Infliximab Biosimilar Landscape Report 2023 by DelveInsight

Infliximab Biosimilar Landscape Report 2023 by DelveInsight

May 04
20:45 2023
Infliximab Biosimilar Landscape Report 2023 by DelveInsight
Infliximab Biosimilar Landscape Report 2023 by DelveInsight
DelveInsight’s, “Infliximab Biosimilar Insight, 2023” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight launched a new report on Infliximab Biosimilar Insights 2023.

DelveInsight’s, “Infliximab Biosimilar Insight, 2023” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Infliximab Overview:

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease.

Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signaling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α 1, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α 1

Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight

Infliximab Biosimilars Marketed Drugs

  • Inflectra: Celltrion/Pfizer
  • Renflexis: Merck

Infliximab Biosimilars Emerging Drugs

  • BCD 055: Biocad
  • CT-P17: Celltrion

Click here and get access to free sample pages of the Infliximab Biosimilar report

Table of contents:

1. Key Insights

2. Infliximab Biosimilars: Snapshot

3. Executive Summary

4. Regulatory Outlook For Biosimilars

5. Infliximab (Reference Product: Remicade)

6. Research and Development

7. Remicade Biosimilar: Emerging Opportunities

8. Infliximab: Biosimilars Assessment

9. Infliximab Biosimilars Profiles: By Company

10. Infliximab Biosimilars: Comparative Landscape: By Company

11. Infliximab Biosimilars: Competitive Landscape

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix 

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Download free sample Infliximab Biosimilar report: https://www.delveinsight.com/report-store/infliximab-biosimilars-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories